Prochlorperazine (oral): Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Pratik Bahekar (talk | contribs)
nocaptcha
3,696 edits
Deepika Beereddy (talk | contribs)
nocaptcha
6,051 edits
No edit summary
Line 1: Line 1:
__NOTOC__
{{DrugProjectFormSinglePage
{{Prochlorperazine}}
|authorTag=
{{CMG}}; {{AE}} {{PB}}


'''''For patient information about Prochlorperazine, click [[Prochlorperazine (patient information)|here]].'''''


{{SB}} <sup>®</sup>,
<!--Overview-->


==Overview==
|genericName=
{{drugbox |
 
| IUPAC_name = 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-<BR>10''H''-phenothiazine
 
| image = Prochlorperazine.svg
 
| CAS_number = 58-38-8
|aOrAn=
| ATC_prefix = N05
 
| ATC_suffix = AB04
a
| PubChem = 4917
 
| DrugBank = APRD00624
|drugClass=
| C = 20 |H = 24 |Cl = 1 |N = 3 |S = 1
 
| molecular_weight = 373.943 [[Gram|g]]/[[Mole (unit)|mol]]
 
| bioavailability = not exactly known, but substantial
 
| protein_bound = 91–99%
|indication=
| metabolism = Mainly [[Liver|hepatic]] ([[CYP2D6]] and/or [[CYP3A4]])
 
| elimination_half-life = 4-8 hours, differs with the mode of application
 
| excretion = Biliary, (colored) inactive metabolites in urine
 
| pregnancy_category = C <small>([[Australia|Au]], [[United States|U.S.]])</small>
|hasBlackBoxWarning=
| legal_status = OTC/[[Prescription drug|POM]] <small>([[United Kingdom|UK]])</small>
 
| routes_of_administration = Oral, buccal, [[Suppository|rectal]], [[Intramuscular injection|IM]]
Yes
}}
 
'''Prochlorperazine''' (marketed under the names '''Compazine''', '''Buccastem''', '''Stemetil''', '''Phenotil''') is a drug that belongs to the [[phenothiazine]] class of antipsychotic agent that is used for the treatment of [[nausea]] and [[vertigo (medical)|vertigo]]. It is also a [[typical antipsychotic]] drug and a highly potent [[neuroleptic]], 10 to 20 times more potent than [[chlorpromazine]]. In [[Pakistan]], it is marketed under the name Phenotil by Unexo Labs.
|adverseReactions=
 
 
 
<!--Black Box Warning-->
 
|blackBoxWarningTitle=
Title
 
|blackBoxWarningBody=
<i><span style="color:#FF0000;">ConditionName: </span></i>
 
* Content
 
<!--Adult Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Adult)-->
 
|fdaLIADAdult=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
 
|offLabelAdultGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Non–Guideline-Supported Use (Adult)-->
 
|offLabelAdultNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
<!--Pediatric Indications and Dosage-->
 
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
 
|fdaLIADPed=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
 
|offLabelPedGuideSupport=
 
=====Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Non–Guideline-Supported Use (Pediatric)-->
 
|offLabelPedNoGuideSupport=
 
=====Condition1=====
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Contraindications-->
 
|contraindications=
 
* Condition1
 
<!--Warnings-->
 
|warnings=
 
* Description
 
====Precautions====
 
* Description
 
<!--Adverse Reactions-->
 
<!--Clinical Trials Experience-->
 
|clinicalTrials=
 
There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
 
=====Cardiovascular=====
 
 
 
 
=====Digestive=====
 
 
 
 
=====Endocrine=====
 
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
 
=====Metabolic and Nutritional=====
 
 
 
 
=====Musculoskeletal=====
 
 
 
 
=====Neurologic=====
 
 
 
 
=====Respiratory=====
 
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
 
=====Special Senses=====
 
 
 
 
=====Urogenital=====
 
 
 
 
=====Miscellaneous=====
 
 
 
<!--Postmarketing Experience-->
 
|postmarketing=
 
There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
 
=====Body as a Whole=====
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
 
|drugInteractions=
 
* Drug
:* Description
 
<!--Use in Specific Populations-->
 
|useInPregnancyFDA=
* '''Pregnancy Category'''
 
|useInPregnancyAUS=
* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
 
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
 
|useInLaborDelivery=
There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
 
|useInNursing=
There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
 
|useInPed=
There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
 
|useInGeri=
There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
 
|useInGender=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific gender populations.
 
|useInRace=
There is no FDA guidance on the use of {{PAGENAME}} with respect to specific racial populations.
 
|useInRenalImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with renal impairment.
 
|useInHepaticImpair=
There is no FDA guidance on the use of {{PAGENAME}} in patients with hepatic impairment.
 
|useInReproPotential=
There is no FDA guidance on the use of {{PAGENAME}} in women of reproductive potentials and males.
 
|useInImmunocomp=
There is no FDA guidance one the use of {{PAGENAME}} in patients who are immunocompromised.
 
<!--Administration and Monitoring-->
 
|administration=
 
* Oral
 
* Intravenous
 
|monitoring=
 
There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
 
* Description
 
<!--IV Compatibility-->
 
|IVCompat=
 
There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
 
<!--Overdosage-->
 
|overdose=
 
===Acute Overdose===
 
====Signs and Symptoms====
 
* Description
 
====Management====
 
* Description
 
===Chronic Overdose===
 
There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacology-->
 
<!--Drug box 2-->
 
|drugBox=
 
 
 
<!--Mechanism of Action-->
 
|mechAction=
 
*
 
<!--Structure-->
 
|structure=
 
*
 
: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
<!--Pharmacodynamics-->
 
|PD=
 
There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
 
<!--Pharmacokinetics-->
 
|PK=
 
There is limited information regarding <i>Pharmacokinetics</i> of {{PAGENAME}} in the drug label.
 
<!--Nonclinical Toxicology-->
 
|nonClinToxic=
 
There is limited information regarding <i>Nonclinical Toxicology</i> of {{PAGENAME}} in the drug label.
 
<!--Clinical Studies-->


==Indications==
|clinicalStudies=
It is now relatively seldom used for the treatment of [[psychosis]] and the [[manic]] phase of [[bipolar disorder]]. It has a prominent antiemetic/antivertiginoic activity and is most often used for the (short-time) treatment of nausea and vomiting and [[Vertigo (medical)|vertigo]] as follows:


# To alleviate the symptoms of vertigo
There is limited information regarding <i>Clinical Studies</i> of {{PAGENAME}} in the drug label.
# As an [[antiemetic]], particularly for nausea and vomiting caused by [[cancer treatment]], [[radiation]] and [[Postoperative nausea and vomiting|in the pre- and postoperative setting]]
# Quite recently, in the UK prochlorperazine maleate has been made available as Buccastem M in [[buccal]] form as an over-the-counter treatment for migraine. In this indication it blocks the [[chemoreceptor trigger zone]] (CTZ) in the brain, which is responsible for causing severe nausea and vomiting. Its OTC use is strictly restricted to a maximum of 2 days, because of the potentially severe [[adverse drug reaction|side effect]]s of prochlorperazine, which mandate supervision by a health care provider.


==Formulations and pharmacokinetics==
<!--How Supplied-->
Prochlorperazine is available as an oral liquid, tablets, and suppositories, as well as in an injectable form.


Following intramuscular injection the antiemetic action is evident within 5 to 10 minutes and lasts for 3 to 4 hours. Rapid action is also noted after buccal treatment. With oral dosing the start of action is delayed but the duration somewhat longer (approximately 6 hours).
|howSupplied=


There is an inhaled form of prochlorperazine under development by Alexza Pharmaceuticals, currently in Phase II clinical trials.
*


==Side effects==
<!--Patient Counseling Information-->
{{see|Typical antipsychotic}}
Due to the short duration of treatment it is usually well tolerated. It shares in general all side effects of [[chlorpromazine]], but these are seen less frequently so and are less disturbing to the patient, particularly as most patients with the aforementioned conditions are hospitalized. In the treatment of nauses/emesis it might be given together with an antiparkinsonian drug to prevent extrapyramidal side effects of prochlorperazine.


Some individuals are inherently allergic to this medicine. This medicine is known to produce [[seizures]] and seizure-like symptoms in individuals who might not have had prior seizures. In such cases, contact health-care facilities for immediate attention. Long-term delays might lead to long-term effects. In extreme cases, it has been known to produce permanent damage to the lower jaw and the jaw joint due to extended seizure symptoms.
|fdaPatientInfo=


If treating psychotic conditions on a long-term basis, the high incidence of early and late ([[tardive dyskinesia]]) extrapyramidal side effects should be considered carefully. Prochlorperazine has in the long-term treatment approximately the same incidence and severity of extrapyramidal side effects as [[haloperidol]].
There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
==Category==


==FDA Package Insert==
<!--Precautions with Alcohol-->
==COMPAZINE (prochlorperazine) suppository==


'''  [[COMPAZINE (prochlorperazine) suppository indications and usage|Indications and Usage]]'''
|alcohol=
'''| [[COMPAZINE (prochlorperazine) suppository dosage and administration|Dosage and Administration]]'''
'''| [[COMPAZINE (prochlorperazine) suppository dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[COMPAZINE (prochlorperazine) suppository contraindications|Contraindications]]'''
'''| [[COMPAZINE (prochlorperazine) suppository warnings and precautions|Warnings and Precautions]]'''
'''| [[COMPAZINE (prochlorperazine) suppository adverse reactions|Adverse Reactions]]'''
'''| [[COMPAZINE (prochlorperazine) suppository drug interactions|Drug Interactions]]'''
'''| [[COMPAZINE (prochlorperazine) suppository use in specific populations|Use in Specific Populations]]'''
'''| [[COMPAZINE (prochlorperazine) suppository overdosage|Overdosage]]'''
'''| [[COMPAZINE (prochlorperazine) suppository description|Description]]'''
'''| [[COMPAZINE (prochlorperazine) suppository clinical pharmacology|Clinical Pharmacology]]'''
'''| [[COMPAZINE (prochlorperazine) suppository nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[COMPAZINE (prochlorperazine) suppository clinical studies|Clinical Studies]]'''
'''| [[COMPAZINE (prochlorperazine) suppository how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[COMPAZINE (prochlorperazine) suppository patient counseling information|Patient Counseling Information]]'''
'''| [[COMPAZINE (prochlorperazine) suppository labels and packages|Labels and Packages]]'''


==PROCHLORPERAZINE EDISYLATE injection==
* Alcohol-{{PAGENAME}} interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.


'''  [[PROCHLORPERAZINE EDISYLATE injection indications and usage|Indications and Usage]]'''
<!--Brand Names-->
'''| [[PROCHLORPERAZINE EDISYLATE injection dosage and administration|Dosage and Administration]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection contraindications|Contraindications]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection warnings and precautions|Warnings and Precautions]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection adverse reactions|Adverse Reactions]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection drug interactions|Drug Interactions]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection use in specific populations|Use in Specific Populations]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection overdosage|Overdosage]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection description|Description]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection clinical pharmacology|Clinical Pharmacology]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection clinical studies|Clinical Studies]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection patient counseling information|Patient Counseling Information]]'''
'''| [[PROCHLORPERAZINE EDISYLATE injection labels and packages|Labels and Packages]]'''


==PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet==
|brandNames=
'''  [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet indications and usage|Indications and Usage]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet dosage and administration|Dosage and Administration]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet dosage forms and strengths|Dosage Forms and Strengths]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet contraindications|Contraindications]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet warnings and precautions|Warnings and Precautions]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet adverse reactions|Adverse Reactions]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet drug interactions|Drug Interactions]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet use in specific populations|Use in Specific Populations]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet overdosage|Overdosage]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet description|Description]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet clinical pharmacology|Clinical Pharmacology]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet nonclinical toxicology|Nonclinical Toxicology]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet clinical studies|Clinical Studies]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet how supplied storage and handling|How Supplied/Storage and Handling]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet patient counseling information|Patient Counseling Information]]'''
'''| [[PROCHLORPERAZINE MALEATE (prochlorperazine maleate) tablet labels and packages|Labels and Packages]]'''


* ®<ref>{{Cite web | title =  | url =  }}</ref>


==Mechanism of Action==
<!--Look-Alike Drug Names-->
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = COMPAZINE (PROCHLORPERAZINE) SUPPOSITORY [PBM PHARMACEUTICALS, INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9bdba30b-53b4-427a-af74-7a39b52130b2 | publisher =  | date =  | accessdate = }}</ref><ref >{{Cite web  | last =  | first =  | title = PROCHLORPERAZINE EDISYLATE INJECTION [BAXTER HEALTHCARE CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e771ba7-983f-49b4-a1f2-0f335b637433 | publisher =  | date =  | accessdate = }}</ref><ref>{{Cite web  | last =  | first =  | title = PROCHLORPERAZINE EDISYLATE INJECTION [BAXTER HEALTHCARE CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5e771ba7-983f-49b4-a1f2-0f335b637433 | publisher =  | date =  | accessdate = }}</ref>
==References==


{{Reflist|2}}
|lookAlike=


{{Antimigraine preparations}}
* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
[[Category:Drugs]]


<!--Drug Shortage Status-->


|drugShortage=
}}


<!--Pill Image-->


{{PillImage
|fileName=No image.jpg|This image is provided by the National Library of Medicine.
|drugName=
|NDC=
|drugAuthor=
|ingredients=
|pillImprint=
|dosageValue=
|dosageUnit=
|pillColor=
|pillShape=
|pillSize=
|pillScore=
}}


<!--Label Display Image-->


==External links==
{{LabelImage
*[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a682116.html Prochlorperazine] medlineplus.org article
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
*[http://www.leaddiscovery.co.uk/pr/Alexza_Initiates_AZ-001_Phase_IIb_Clinical_Trial_in_Patients_With_Migraine_Headaches.html AZ-001 (Staccato(TM) prochlorperazine)] Press release pertaining to phase IIb clinical trial of inhaled prochlorperazine for migraine headache
}}
 
{{LabelImage
|fileName={{PAGENAME}}11.png|This image is provided by the National Library of Medicine.
}}


{{Antipsychotics}}
<!--Category-->
[[ru:Прохлорперазин]]
[[sv:Proklorperazin]]
sex


[[Category:Typical antipsychotics]]
[[Category:Drug]]
[[Category:Antiemetics]]
[[Category:Phenothiazines]]
[[Category:Drugs]]

Revision as of 17:02, 28 November 2014

Prochlorperazine (oral)
Black Box Warning
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content

Overview

Prochlorperazine (oral) is a that is FDA approved for the {{{indicationType}}} of . There is a Black Box Warning for this drug as shown here. Common adverse reactions include .

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1
  • Dosing Information
  • Dosage
Condition2
  • Dosing Information
  • Dosage
Condition3
  • Dosing Information
  • Dosage
Condition4
  • Dosing Information
  • Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Prochlorperazine (oral) in adult patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Prochlorperazine (oral) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding FDA-Labeled Use of Prochlorperazine (oral) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1
  • Developed by:
  • Class of Recommendation:
  • Strength of Evidence:
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Prochlorperazine (oral) in pediatric patients.

Non–Guideline-Supported Use

Condition1
  • Dosing Information
  • Dosage
Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Prochlorperazine (oral) in pediatric patients.

Contraindications

  • Condition1

Warnings

Title
See full prescribing information for complete Boxed Warning.
ConditionName:
  • Content
  • Description

Precautions

  • Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Prochlorperazine (oral) in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Prochlorperazine (oral) in the drug label.

Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous

Drug Interactions

  • Drug
  • Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • Pregnancy Category


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Prochlorperazine (oral) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Prochlorperazine (oral) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Prochlorperazine (oral) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Prochlorperazine (oral) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Prochlorperazine (oral) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Prochlorperazine (oral) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Prochlorperazine (oral) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Prochlorperazine (oral) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Prochlorperazine (oral) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Prochlorperazine (oral) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Prochlorperazine (oral) in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Oral
  • Intravenous

Monitoring

There is limited information regarding Monitoring of Prochlorperazine (oral) in the drug label.

  • Description

IV Compatibility

There is limited information regarding IV Compatibility of Prochlorperazine (oral) in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

  • Description

Management

  • Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Prochlorperazine (oral) in the drug label.

Pharmacology

There is limited information regarding Prochlorperazine (oral) Pharmacology in the drug label.

Mechanism of Action

Structure

File:Prochlorperazine (oral)01.png
This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Prochlorperazine (oral) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Prochlorperazine (oral) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Prochlorperazine (oral) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Prochlorperazine (oral) in the drug label.

How Supplied

Storage

There is limited information regarding Prochlorperazine (oral) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Prochlorperazine (oral) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Prochlorperazine (oral) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Prochlorperazine (oral) in the drug label.

Precautions with Alcohol

  • Alcohol-Prochlorperazine (oral) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Empty citation (help)
  2. ↑ "http://www.ismp.org". External link in |title= (help)


{{#subobject: 

 |Page Name=Prochlorperazine (oral)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}


{{#subobject: 

 |Label Page=Prochlorperazine (oral)
 |Label Name=Prochlorperazine (oral)11.png

}}


{{#subobject: 

 |Label Page=Prochlorperazine (oral)
 |Label Name=Prochlorperazine (oral)11.png

}}

Retrieved from "https://www.wikidoc.org/index.php?title=Prochlorperazine_(oral)&oldid=1043557"